First Patients Dosed in our Ultra-rare Disease Study

VCTC are pleased to share a milestone moment at our Sheffield clinic this week.

We have successfully dosed our first paediatric patients as part of our ongoing ultra-rare disease study.

Two young children - one local to Sheffield and one travelling from Denmark - received treatment at our Channing Hall location. This marks an exciting progression in a study that began with six adult participants.

VCTC Director of Global Operations, Dr Ann Church , said:

"It was great to welcome our paediatric patients and their families to our clinic this week, and we look forward to sharing their journey on this study over the coming months"

Want to learn more about how we’re making decentralised trials work for ultra-rare conditions? Read the case study here